Clinical Report: Acute Kidney Injury Therapies Reviewed
Overview
A recent review highlights the lack of proven targeted interventions for acute kidney injury (AKI) in critical care. While several therapies show potential, including intravenous amino acids and inorganic nitrates, no pharmacological treatment has been established for routine clinical use.
Background
Acute kidney injury (AKI) is a common and serious complication in critically ill patients, with incidence rates ranging from 20% to 75%. It is associated with significant morbidity, including chronic dialysis dependence and increased mortality. Current strategies primarily focus on preventing further deterioration of renal function, as no approved therapies exist for AKI treatment.
Data Highlights
| Study | Intervention | AKI Incidence |
|---|---|---|
| PROTECTION trial | Intravenous balanced amino acids | 27% vs 32% (placebo) |
| NITRATE-CIN trial | Oral inorganic nitrate | 9% vs 31% (placebo) |
| Dexmedetomidine trial | Dexmedetomidine | 18% vs 33% (placebo) |
| Another Dexmedetomidine trial | Dexmedetomidine | 35% vs 50% (placebo) |
Key Findings
- Intravenous balanced amino acids reduced AKI incidence in cardiac surgery patients (27% vs 32% placebo).
- Oral inorganic nitrate lowered contrast-induced AKI incidence in coronary angiography patients (9% vs 31% placebo).
- Dexmedetomidine showed a reduced AKI risk in perioperative settings (18% vs 33% and 35% vs 50% in different trials).
- Sodium-glucose cotransporter 2 inhibitors were associated with a 28% lower risk of AKI in chronic-use populations.
- Angiotensin II was linked to lower mortality and more renal replacement therapy-free days in stage 3 AKI patients.
- Device-based approaches like Cytosorb therapy showed variable outcomes in renal recovery.
Clinical Implications
The findings suggest that while certain interventions may reduce the incidence of AKI, their impact on long-term kidney function and survival remains unclear. Clinicians should remain cautious in interpreting these results and consider individual patient mechanisms of injury when evaluating treatment options.
Conclusion
The review underscores the complexity of AKI management in critical care, highlighting the need for further research to establish effective therapies.
Related Resources & Content
- Emerging Pharmacological Therapies for Acute Kidney Injury, Intensive Care Medicine, 2022
- Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review, Critical Care, 2025
- Multidisciplinary guidelines on renal replacement therapy in intensive care medicine, Critical Care, 2025
- Strategies for Preventing Acute Kidney Injury and Preserving Renal Function in Intensive Care Settings: A 2017 Update, Intensive Care Medicine
- KDIGO Announces Update to AKI Guideline, KDIGO
- Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury, New England Journal of Medicine
- Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL), PMC
- KDIGO Announces Update to AKI Guideline – KDIGO
- Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury | New England Journal of Medicine
- Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
